08-12-2001, 07:25 AM
he is Dc.Jeffrey Rothstein and works at the Johns Hopkins with,I think, Dc.Gearhart.I read an his article last Agoust about motoneurons loss for ALS.
Please,I do not understand what you think on work of Dc.Gearhart for polio.(sorry my english,but I am an italian!!!)
08-13-2001, 12:43 AM
I know which Dr. Rothstein you are referring to. I think that Dr. Gearhart's studies are very promising for ALS and for polio. Although the stem cells did not produce new motoneurons in mice with ALS, it did improve their survival and walking recovery.
[This message was edited by Wise Young on August 13, 2001 at 06:53 AM.]
08-18-2001, 11:24 AM
Send your email address to OldDrooler@hcnews.com and I will try to answer your questions. Also, I have one or two for you.
08-19-2001, 09:43 AM
•Bar-Peled O, Ben-Hur H, Biegon A et al. Distribution of glutamate transporter subtypes during human brain development. J Neurochem 1997; 69(6):2571-80.
•Bar-Peled O, Knudson M, Korsmeyer SJ et al. Motor neuron degeneration is attenuated in bax-deficient neurons in vitro. J Neurosci Res 1999; 55(5):542-56.
•Bar-Peled O, O'Brien RJ, Morrison JH et al. Cultured motor neurons possess calcium-permeable AMPA/kainate receptors. Neuroreport 1999; 10(4):855-9.
•Bristol LA, Rothstein JD. Glutamate transporter gene expression in amyotrophic lateral sclerosis motor cortex. Ann Neurol 1996; 39(5):676-9.
•Bristol LA, Rothstein JD. Use of antisense oligodeoxynucleotides to inhibit expression of glutamate transporter subtypes. Methods Enzymol 1998; 296(514-29.
•Corse AM, Bilak MM, Bilak SR et al. Preclinical testing of neuroprotective neurotrophic factors in a model of chronic motor neuron degeneration. Neurobiol Dis 1999; 6(5):335-46.
•Drachman DB, Fishman PS, Rothstein JD et al. Amyotrophic lateral sclerosis. An autoimmune disease? Adv Neurol 1995; 68(59-65.
•Drachman DB, Rothstein JD. Inhibition of cyclooxygenase-2 protects motor neurons in an organotypic model of amyotrophic lateral sclerosis. Ann Neurol 2000; 48(5):792-5.
•Furuta A, Martin LJ, Lin CL et al. Cellular and synaptic localization of the neuronal glutamate transporters excitatory amino acid transporter 3 and 4. Neuroscience 1997; 81(4):1031-42.
•Furuta A, Rothstein JD, Martin LJ. Glutamate transporter protein subtypes are expressed differentially during rat CNS development. J Neurosci 1997; 17(21):8363-75.
•Ginsberg SD, Martin LJ, Rothstein JD. Regional deafferentation down-regulates subtypes of glutamate transporter proteins. J Neurochem 1995; 65(6):2800-3.
•Ginsberg SD, Rothstein JD, Price DL et al. Fimbria-fornix transections selectively down-regulate subtypes of glutamate transporter and glutamate receptor proteins in septum and hippocampus. J Neurochem 1996; 67(3):1208-16.
•Glass JD, Levey AI, Rothstein JD. The dysarthria-clumsy hand syndrome: a distinct clinical entity related to pontine infarction. Ann Neurol 1990; 27(5):487-94.
•Ho TW, Bristol LA, Coccia C et al. TGFbeta trophic factors differentially modulate motor axon outgrowth and protection from excitotoxicity. Exp Neurol 2000; 161(2):664-75.
•Jackson M, Song W, Liu MY et al. Modulation of the neuronal glutamate transporter EAAT4 by two interacting proteins. Nature 2001; 410(6824):89-93.
•Jinnah HA, Jones MD, Wojcik BE et al. Influence of age and strain on striatal dopamine loss in a genetic mouse model of Lesch-Nyhan disease. J Neurochem 1999; 72(1):225-9.
•Jinnah HA, Sepkuty JP, Ho T et al. Calcium channel agonists and dystonia in the mouse. Mov Disord 2000; 15(3):542-51.
•Jinnah HA, Yitta S, Drew T et al. Calcium channel activation and self-biting in mice. Proc Natl Acad Sci U S A 1999; 96(26):15228-32.
•Lin CI, Orlov I, Ruggiero AM et al. Modulation of the neuronal glutamate transporter EAAC1 by the interacting protein GTRAP3-18. Nature 2001; 410(6824):84-8.
•Lin CL, Bristol LA, Jin L et al. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 1998; 20(3):589-602.
•Lin CL, Tzingounis AV, Jin L et al. Molecular cloning and expression of the rat EAAT4 glutamate transporter subtype. Brain Res Mol Brain Res 1998; 63(1):174-9.
•Maragakis NJ, Rothstein JD. Glutamate transporters in neurologic disease. Arch Neurol 2001; 58(3):365-70.
•Martin LJ, Brambrink AM, Lehmann C et al. Hypoxia-ischemia causes abnormalities in glutamate transporters and death of astroglia and neurons in newborn striatum. Ann Neurol 1997; 42(3):335-48.
•Northington FJ, Traystman RJ, Koehler RC et al. Regional and cellular expression of glial (GLT1) and neuronal (EAAC1) glutamate transporter proteins in ovine fetal brain. Neuroscience 1998; 85(4):1183-94.
•O'Brien RJ, Mammen AL, Blackshaw S et al. The development of excitatory synapses in cultured spinal neurons. J Neurosci 1997; 17(19):7339-50.
•Rothstein JD. Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. Adv Neurol 1995; 68(7-20.
•Rothstein JD. Excitotoxicity and neurodegeneration in amyotrophic lateral sclerosis. Clin Neurosci 1995; 3(6):348-59.
•Rothstein JD. Excitotoxicity hypothesis. Neurology 1996; 47(4 Suppl 2):S19-25; discussion S6.
•Rothstein JD. Therapeutic horizons for amyotrophic lateral sclerosis. Curr Opin Neurobiol 1996; 6(5):679-87.
•Rothstein JD, Bristol LA, Hosler B et al. Chronic inhibition of superoxide dismutase produces apoptotic death of spinal neurons. Proc Natl Acad Sci U S A 1994; 91(10):4155-9.
•Rothstein JD, Dykes-Hoberg M, Corson LB et al. The copper chaperone CCS is abundant in neurons and astrocytes in human and rodent brain. J Neurochem 1999; 72(1):422-9.
•Rothstein JD, Dykes-Hoberg M, Pardo CA et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 1996; 16(3):675-86.
•Rothstein JD, Garland W, Puia G et al. Purification and characterization of naturally occurring benzodiazepine receptor ligands in rat and human brain. J Neurochem 1992; 58(6):2102-15.
•Rothstein JD, Guidotti A, Costa E. Release of endogenous benzodiazepine receptor ligands (endozepines) from cultured neurons. Neurosci Lett 1992; 143(1-2):210-4.
•Rothstein JD, Guidotti A, Tinuper P et al. Endogenous benzodiazepine receptor ligands in idiopathic recurring stupor. Lancet 1992; 340(8826):1002-4.
•Rothstein JD, Herlong HF. Neurologic manifestations of hepatic disease. Neurol Clin 1989; 7(3):563-78.
•Rothstein JD, Jin L, Dykes-Hoberg M et al. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc Natl Acad Sci U S A 1993; 90(14):6591-5.
•Rothstein JD, Kuncl RW. Neuroprotective strategies in a model of chronic glutamate-mediated motor neuron toxicity. J Neurochem 1995; 65(2):643-51.
•Rothstein JD, Martin L, Levey AI et al. Localization of neuronal and glial glutamate transporters. Neuron 1994; 13(3):713-25.
•Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 1992; 326(22):1464-8.
•Rothstein JD, McKhann G, Guarneri P et al. Cerebrospinal fluid content of diazepam binding inhibitor in chronic hepatic encephalopathy. Ann Neurol 1989; 26(1):57-62.
•Rothstein JD, Olasmaa M. Endogenous GABAergic modulators in the pathogenesis of hepatic encephalopathy. Neurochem Res 1990; 15(2):193-7.
•Rothstein JD, Tsai G, Kuncl RW et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990; 28(1):18-25.
•Rothstein JD, Van Kammen M, Levey AI et al. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995; 38(1):73-84.
•Rothstein NM, Quinn TC, Madico G et al. Effect of azithromycin on murine arteriosclerosis exacerbated by Chlamydia pneumoniae. J Infect Dis 2001; 183(2):232-8.
•Tsai GC, Stauch-Slusher B, Sim L et al. Reductions in acidic amino acids and N-acetylaspartylglutamate in amyotrophic lateral sclerosis CNS. Brain Res 1991; 556(1):151-6.
•Vos CM, Sjulson L, Nath A et al. Cytotoxicity by matrix metalloprotease-1 in organotypic spinal cord and dissociated neuronal cultures. Exp Neurol 2000; 163(2):324-30.
•Wong PC, Rothstein JD, Price DL. The genetic and molecular mechanisms of motor neuron disease. Curr Opin Neurobiol 1998; 8(6):791-9.
•Wong PC, Waggoner D, Subramaniam JR et al. Copper chaperone for superoxide dismutase is essential to activate mammalian Cu/Zn superoxide dismutase. Proc Natl Acad Sci U S A 2000; 97(6):2886-91.
08-19-2001, 09:45 AM
Are you interested in the reasons why motoneurons die? This appears to be the main thrust of much of Dr. Rothsteins work. I thought that you were interested in work that pertains to restoration or replacement of motoneurons. Wise.